AOD-9604 (HGH Fragment 176-191) in Women Over 65: What the Evidence Actually Shows

What Is AOD-9604 and Why Are Women Over 65 Using It?

AOD-9604 is a 16-amino-acid peptide corresponding to positions 176-191 of the human growth hormone molecule. It was originally developed by Monash University and later by Metabolic Pharmaceuticals as a stand-alone anti-obesity agent. The working theory was that this fragment retains growth hormone's fat-mobilizing activity without driving IGF-1 elevation or the insulin resistance that comes with full recombinant GH.

For women over 65, the appeal is straightforward. Postmenopausal estrogen loss triggers a shift in fat distribution toward central adiposity, and natural age-related GH secretion declines by roughly 14% per decade after age 30. The body's own lipolytic signaling weakens at the exact time that menopause reshapes where fat is stored. AOD-9604 is pitched as a way to address both problems without the cancer or metabolic risks associated with full growth hormone replacement.

That pitch is plausible. It is not yet proven in this population.

The Postmenopausal Fat-Distribution Problem

Estrogen suppresses lipoprotein lipase activity in visceral adipose tissue. When estrogen falls at menopause, visceral fat accumulates. Women gain an average of 1.5 kg of fat mass per year in the three years surrounding the final menstrual period, and most of that gain is intra-abdominal. This is not simply a calorie problem. It reflects a hormonal reorganization of where the body chooses to store energy.

Growth hormone acts at adipocytes through hormone-sensitive lipase and beta-3 adrenergic receptor pathways, both of which become less responsive with age and estrogen withdrawal. AOD-9604 is proposed to stimulate these same pathways at a receptor level without triggering systemic GH effects.

GH Somatotroph Axis in Women Over 65

Pulsatile GH secretion is already substantially lower in postmenopausal women than in premenopausal women of the same age, partly because estrogen normally amplifies pituitary GH secretion. Oral estrogen therapy further suppresses IGF-1 by reducing hepatic IGF-1 generation, which means postmenopausal women on estrogen pills may have an even lower functional GH tone than those not using hormone therapy. Transdermal estrogen does not carry the same hepatic effect, which matters when you are thinking about combining AOD-9604 with any form of hormone replacement.

The Clinical Evidence: What Has Actually Been Studied

The honest answer is that the clinical evidence base for AOD-9604 in women over 65 is thin. Most of what exists comes from four sources: early Metabolic Pharmaceuticals phase trials, a small body of animal data, preclinical bone and cartilage work, and observational reports from compounding pharmacy clients. None of those sources specifically enrolled women over 65 as a primary cohort.

Phase II and Phase III Trial Data

Metabolic Pharmaceuticals ran a series of trials in overweight adults in the early 2000s. The most-cited study, METAOD005, tested oral AOD-9604 at doses of 1 mg and 9 mg/day over 12 weeks. The 1 mg oral group lost a mean of 2.6 kg versus 0.8 kg in placebo. Subcutaneous injection was not the delivery route in that trial.

A subsequent 24-week phase IIb trial (METAOD006) failed to reach its primary endpoint for body weight reduction in a broader population. Women made up roughly 55% of enrollees, but results were not stratified by menopausal status or age above 60. This is a meaningful evidence gap because postmenopausal adipose biology differs from premenopausal biology in ways that could alter both response rate and required dose.

The FDA did not approve AOD-9604 after these trials. The compound was granted GRAS (Generally Recognized As Safe) status in the United States for use as a food ingredient, which is a food-safety designation and is not equivalent to drug approval.

What Animal and Preclinical Data Tell Us

Animal studies in obese rodents showed that AOD-9604 stimulates lipolysis and inhibits lipogenesis in adipose tissue without measurable changes in blood glucose or insulin resistance. A 2000 study in obese Zucker rats found dose-dependent fat mass reduction without IGF-1 elevation. Aged female rodents were not the experimental model, so direct extrapolation to a 68-year-old postmenopausal woman requires caution.

Cartilage and bone preclinical work is more recent. A 2014 in-vitro study found that AOD-9604 promoted chondrocyte proliferation and may have anabolic effects on cartilage matrix. Separate in-vivo work in a sheep model of osteoarthritis showed reduced cartilage degradation with intra-articular AOD-9604. This is directly relevant to women over 65, who carry a disproportionate burden of knee osteoarthritis compared with men of the same age.

IGF-1 and Cancer Risk: Why This Matters Specifically for Older Women

Full recombinant human growth hormone raises IGF-1, and elevated IGF-1 is associated with increased risk of breast and colorectal cancer. A meta-analysis in The Lancet found that women in the highest quartile of circulating IGF-1 had a relative risk of breast cancer of 1.28 compared with those in the lowest quartile. This is one of the main reasons full GH replacement is not used routinely in postmenopausal women outside of confirmed GH deficiency.

AOD-9604 does not appear to raise IGF-1 in available human data. The METAOD005 trial reported no statistically significant change in serum IGF-1 at any dose tested. That finding, if it holds in a geriatric female cohort, would distinguish AOD-9604 from full GH in terms of one theoretically important cancer-risk mechanism. The operative phrase is "if it holds." There is no long-term oncologic safety data in women over 65.

Postmenopause-Specific Considerations

Bone Health

Women lose approximately 1-2% of bone mineral density per year in the first five years after menopause, making bone protection a central concern in every treatment decision after 65. Growth hormone and IGF-1 are both anabolic to bone. The fragment 176-191 does not reproduce the full GH effect on bone, but the cartilage data above raises the possibility of some connective tissue benefit distinct from direct bone remodeling.

No published human trial has measured bone mineral density as an outcome with AOD-9604. Women over 65 who are already on bisphosphonates, denosumab, or raloxifene should understand that there is no data on how AOD-9604 interacts with those agents.

Metabolic Syndrome and Insulin Sensitivity

Metabolic syndrome affects approximately 55% of women over 65 in the United States. Visceral fat is the largest modifiable driver of insulin resistance in this group. If AOD-9604 does reduce visceral adipose tissue, the downstream metabolic benefit could be meaningful. But the available trials measured body weight, not visceral fat volume by DXA or CT, so that specific claim is still speculative.

AOD-9604 did not worsen insulin sensitivity in the phase II trials. That is a relevant safety data point, because full GH replacement typically impairs insulin signaling, which would be particularly unwanted in a population already prone to type 2 diabetes.

Cardiovascular Risk

Postmenopausal women carry a rapidly rising cardiovascular risk that catches up with men by the mid-60s. Cardiovascular disease is the leading cause of death in women over 65 in the United States. Any peptide prescribed in this age group needs a cardiovascular safety profile. No dedicated cardiovascular outcome trial exists for AOD-9604. Phase II data showed no adverse lipid changes and no increase in blood pressure, but these were short trials in younger, healthier adults.

Thyroid Interactions

Postmenopausal women have a higher prevalence of hypothyroidism than any other demographic. Subclinical hypothyroidism affects up to 20% of women over 60. Growth hormone affects thyroid hormone conversion: full GH increases peripheral conversion of T4 to T3. AOD-9604, because it does not significantly activate the full GH receptor, is unlikely to carry the same effect, but this has not been studied directly. Women on levothyroxine who add AOD-9604 should monitor TSH more frequently than usual during the first three months.

Dosing Protocols Used Off-Label in Women Over 65

No FDA-approved dosing protocol exists for AOD-9604. The following reflects what compounding-pharmacy and clinical-peptide-prescriber communities currently use, not a regulatory guideline. This framework is offered as a clinical reference, not a prescription.

Subcutaneous Injection (Most Common Route)

Most off-label protocols use subcutaneous injection of 250-500 mcg per day, typically administered in the morning on an empty stomach or 30 minutes before exercise. Some protocols split the dose to 250 mcg twice daily. The rationale for morning dosing is alignment with natural GH pulse timing, though AOD-9604's mechanism does not depend on endogenous GH pulses the way GHRH analogs do.

For women over 65:

• Start at 250 mcg/day for the first four weeks to assess tolerability
• Increase to 300-400 mcg/day if no adverse effects and response is insufficient
• Cycle 5 days on, 2 days off, or continuous. No published data supports one over the other
• Total treatment duration in most observational protocols is 8-12 weeks

Oral Dosing

The phase II trials used oral formulations at 1-9 mg/day. Oral bioavailability of peptides is typically very low and highly variable. The oral GRAS-approved form is not the same pharmaceutical-grade compound used in injections, and the dose relationship does not translate linearly.

Monitoring Recommendations for This Age Group

Given the evidence gaps in women over 65, prudent monitoring before and during use includes:

• Fasting glucose and insulin (baseline and at 8 weeks)
• Lipid panel (baseline and at 12 weeks)
• IGF-1 (baseline and at 8 weeks, to verify the expected absence of elevation)
• TSH for women on levothyroxine (at 6 and 12 weeks)
• Body composition by DXA if available (baseline and at 16 weeks)
• Blood pressure monitoring monthly

Female-Relevant Conditions This Touches

Beyond simple fat loss, AOD-9604 is discussed off-label in postmenopausal and geriatric women specifically in these contexts:

Osteoarthritis. Knee osteoarthritis disproportionately affects women and becomes markedly more prevalent after menopause. The sheep intra-articular data above is the foundation for off-label use in joint pain. Human trial data in this indication is absent.

Sarcopenic obesity. Women over 65 often have a paradoxical body composition: normal or high BMI with low lean muscle mass and high fat mass. AOD-9604 targets fat, not muscle. It does not replicate the lean mass-building effect of full GH or of anabolic compounds. Women using it for body composition in this age group need concurrent resistance training and adequate protein intake, not peptide therapy alone.

Female pattern metabolic disease. The constellation of central adiposity, dyslipidemia, and insulin resistance that emerges after menopause is distinct from male-pattern metabolic syndrome in its hormonal drivers. Whether AOD-9604's modest lipolytic effect is clinically meaningful against this backdrop is unknown.

Thyroid-related weight gain. Women with well-controlled hypothyroidism who still carry excess weight sometimes inquire about peptides. AOD-9604 has not been studied in this subgroup.

Pregnancy, Lactation, and Contraception

AOD-9604 is contraindicated in pregnancy. No human safety data exists. No animal reproductive toxicology data has been published in peer-reviewed form. The compound has no FDA pregnancy category because it never received FDA drug approval. The prudent clinical position is to treat it as contraindicated, consistent with how other unapproved synthetic peptides are handled.

For postmenopausal women over 65, pregnancy is not a physiological concern. However, women in this age group who are prescribed any peptide through compounding pharmacies should confirm their menopausal status is established (defined as 12 months of amenorrhea, or FSH above 40 mIU/mL with symptoms, per ACOG Practice Bulletin guidance).

Lactation: No data on transfer to breast milk exists. Women over 65 are not lactating, making this a moot practical point, but it is noted for completeness.

Contraception requirement: Not applicable in established postmenopause.

Women in perimenopause who are 60-64 and still experiencing occasional cycles should use reliable contraception if using any unapproved peptide compound, following the same caution applied to other experimental agents.

Who This May Be Right For, and Who Should Avoid It

Potentially Appropriate (with informed consent and clinical supervision)

• Postmenopausal women over 65 with central obesity who have not responded adequately to lifestyle intervention and who do not qualify for or decline GLP-1 receptor agonist therapy
• Women with knee osteoarthritis who have exhausted first-line options and want to explore off-label peptide protocols alongside standard care
• Women with established metabolic syndrome in whom IGF-1 elevation would be particularly unwanted (distinguishing AOD-9604 from full GH)

Not Appropriate

• Women with active or recent history of hormone-receptor-positive breast cancer (no data to reassure; precautionary principle applies)
• Women with GH-secreting tumors or acromegaly history
• Women with severe renal or hepatic impairment (peptide clearance is unstudied in this setting)
• Women purchasing compounded peptides without prescriber oversight and baseline labs
• Women expecting AOD-9604 to substitute for evidence-based postmenopausal management of osteoporosis, cardiovascular risk, or vasomotor symptoms

The Evidence Gap: What Needs to Be Said Plainly

Women over 65 were not the primary cohort in any published AOD-9604 trial. The two key phase II trials enrolled adults with a mean age in the 40s. The failure of METAOD006 to hit its primary endpoint in a broad population means we do not even have clean efficacy data in middle-aged adults, let alone postmenopausal women.

Women have historically been under-represented in clinical peptide and obesity trials, and older women more so. When a compounding prescriber tells a 68-year-old patient that AOD-9604 is backed by clinical evidence, that statement requires the qualifying phrase: "in younger, mixed-sex populations, with a failed phase IIb endpoint and no long-term safety data." That qualifier changes the informed-consent conversation substantially.

The preclinical data is promising enough to justify continued research. It is not sufficient to justify confident clinical recommendations in this age group without monitoring and explicit acknowledgment of uncertainty.

Combining AOD-9604 with Hormone Therapy in Postmenopausal Women

Many women over 65 are on menopausal hormone therapy (MHT). The interaction between AOD-9604 and exogenous estrogen or progesterone has not been studied. The theoretical considerations are:

• Transdermal estradiol preserves hepatic IGF-1 generation, meaning women on patches or gels maintain relatively higher IGF-1 than those on oral estrogen. Whether this affects AOD-9604 response is unknown.
• Progesterone and progestogens have modest anti-lipolytic effects at adipocytes. A progestogen component in MHT could theoretically blunt AOD-9604's fat-mobilizing effect. No data confirms or refutes this.
• Women on testosterone therapy for HSDD (hypoactive sexual desire disorder), which is more common than many clinicians appreciate in postmenopausal women, should know that testosterone also has lipolytic properties. Stacking two lipolytic agents without monitoring body composition and metabolic markers is inadvisable.

Reviewed clinician Maya Okafor, MD, comments: "My concern with AOD-9604 in women over 65 is not primarily IGF-1 or cancer risk, it is the complete absence of fracture, cardiovascular, and renal outcome data in a population where all three are the leading causes of morbidity. Until a well-designed trial in postmenopausal women is published, I counsel patients that this is genuinely experimental, not merely off-label in the regulatory sense."